Although monoclonal antibody (mAb) blockade of PD-1/PD-L1 has demonstrated significant clinical benefit for various types of human cancers, antibody-based immunotherapies have several limitations such as the high production cost of antibodies, immune-related adverse effects, and drug resistance [63, 64]. This evidence concerns the gene CD274 and cancer.